This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.
In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Actavis, 570 U.S. 136 (2013), [link] opinions/12pdf/12-416_m5n0.pdf.
The combined solution enables health plans and self-insured employers to realize immediate pharmacy cost savings and near-term medical cost reductions by integrating Levrx’s plan-specific and real-time prescription insights into the Adhere Platform medication optimization offerings. PharmaManufacturer Solutions. Vincent Keunen.
Improving our collective understanding of the patient’s overall healthcare experience is necessary to effectively deliver prescription support. How can we ensure that vital prescription information reaches patients when they need it? 4 These statistics tell a story of trust, concern, and changing dynamics in healthcare communication.
It leverages GoodRx’s reach and scale to broaden access and affordability for people living with diabetes and means that all Americans with a valid prescription, regardless of insurance status, can use GoodRx at over 70,000 U.S. The price is available to cash-paying patients with a valid prescription. References: 1.
The cost of filling a prescription can keep 21% of patients from getting an Rx, and one in ten patients will modify their treatment plan because of cost, according to recent polling data from KFF. It all starts with reaching HCPs and pharmacists across POC platforms with program information at the points of prescription and dispensing.
Pharmaceutical wholesalers act as intermediaries between pharmaceuticalmanufacturers and retailers and facilitate the delivery of the right medicines in a timely, efficient, and secure manner. Wholesale distributors are responsible for guaranteeing product quality and preventing the influx of counterfeited drugs.
In this blog, we take a close look at health equity in oncology trials specifically, assessing how the lack of diversity and inclusion has impacted cancer patients and the pharma industry’s key initiatives to address it.
Thus, this article aims to outline the healthcare system and key market access pathways that are opening in China for pharmaceutical products, including vaccines. Additionally, it will delve into the current trends and challenges that pharma companies need to consider when devising successful market access strategies for this unique market.
Although the reported negotiated prices may ignore the real-world role of contracting by manufacturers and private payers over formulary placement, the reported prices nonetheless are likely to have downstream impacts on how private payers reimburse these therapies and their competitors. These ten drugs cost Medicare Part D nearly $46.8
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content